Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease
The balance between immunostimulation and immunoregulation in T cell immunity is achieved by maintaining specific ratios of Th1, Th2, Th3 and Tr1 cells. Here, we investigate levels of type 1 (IFN-gamma; NK1), type 2 (IL-13; NK2), type 3 (TGF-beta; NK3) and regulatory (IL-10; NKr) cytokines in peripheral blood to assess the cytokine profiles of natural killer (NK) cells following human allogeneic hematopoietic stem cell transplantation (allo-HSCT). NK2 and NK3 cell expansion was observed after allo-HSCT; levels of NKr cells reached donor levels at day 15, though levels of NK1 cells were consistently lower than donor levels until day 60 after allo-HSCT. Multivariate analysis showed that a higher level of NK1 cells by day 15 was associated with a lower overall risk of acute graft-versus-host disease (GVHD) (HR 0.157, P=0.010) as well as II-IV acute GVHD (HR 0.260, P=0.059). Furthermore, higher levels of NK1 cells by day 15 were correlated with lower rates of cytomegalovirus (CMV) reactivation (HR 0.040, 0.005–0.348, P=0.003). These results indicate that rapid reconstitution of NK cells, especially NK1 cells, can help prevent the development of GVHD as well as CMV reactivation after allogeneic transplantation.
KeywordsNK1 NK2 NK3 NKr GVHD CMV
Unable to display preview. Download preview PDF.
The authors thank the members of the core facilities at the Peking University Institute of Hematology for sample collection. This work was supported by the National Natural Science Foundation of China (81270644, 81670166, 81230013, 81530046), the Beijing Talents fund (2015000021223ZK26), the Major State Basic Research Development Program of China (2013CB733700) and the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81621001). The study was also partially supported by the Collaborative Innovation Center of Hematology, China.
- Asai, O., Longo, D.L., Tian, Z.G., Hornung, R.L., Taub, D.D., Ruscetti, F. W., and Murphy, W.J. (1998). Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 101, 1835–1842.CrossRefPubMedPubMedCentralGoogle Scholar
- Bunting, M.D., Varelias, A., Souza-Fonseca-Guimaraes, F., Schuster, I.S., Lineburg, K.E., Kuns, R.D., Fleming, P., Locke, K.R., Huntington, N. D., Blazar, B.R., Lane, S.W., Tey, S.K., MacDonald, K.P.A., Smyth, M. J., Degli-Esposti, M.A., and Hill, G.R. (2017). GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. Blood 129, 630–642.CrossRefPubMedPubMedCentralGoogle Scholar
- Fehniger, T.A., Cooper, M.A., Nuovo, G.J., Cella, M., Facchetti, F., Colonna, M., and Caligiuri, M.A. (2003). CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101, 3052–3057.CrossRefPubMedGoogle Scholar
- Goldszmid, R.S., Caspar, P., Rivollier, A., White, S., Dzutsev, A., Hieny, S., Kelsall, B., Trinchieri, G., and Sher, A. (2012). NK cell-derived interferon-γ orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 36, 1047–1059.CrossRefPubMedPubMedCentralGoogle Scholar
- Huang, X.J., Liu, D.H., Liu, K.Y., Xu, L.P., Chen, H., Han, W., Chen, Y.H., Wang, J.Z., Gao, Z.Y., Zhang, Y.C., Jiang, Q., Shi, H.X., and Lu, D.P. (2006). Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38, 291–297.CrossRefPubMedGoogle Scholar
- Huang, X.J., Liu, D.H., Liu, K.Y., Xu, L.P., Chen, Y.H., Wang, Y., Han, W., and Chen, H. (2008a). Modified donor lymphocyte infusion after HLAmismatched/ haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 28, 276–283.CrossRefPubMedGoogle Scholar
- Huang, X.J., Wang, Y., Liu, D.H., Xu, L.P., Chen, H., Chen, Y.H., Han, W., Shi, H.X., and Liu, K.Y. (2008b). Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia—feasibility and safety study. J Clin Immunol 28, 390–397.CrossRefPubMedGoogle Scholar
- Jiang, Q., Xu, L.P., Liu, D.H., Liu, K.Y., Chen, S.S., Jiang, B., Jiang, H., Chen, H., Chen, Y.H., Han, W., Zhang, X.H., Wang, Y., Qin, Y.Z., Liu, Y.R., Lai, Y.Y., and Huang, X.J. (2011). Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117, 3032–3040.CrossRefPubMedGoogle Scholar
- Lu, D.P., Dong, L., Wu, T., Huang, X.J., Zhang, M.J., Han, W., Chen, H., Liu, D.H., Gao, Z.Y., Chen, Y.H., Xu, L.P., Zhang, Y.C., Ren, H.Y., Li, D., and Liu, K.Y. (2006). Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107, 3065–3073.CrossRefPubMedGoogle Scholar
- Lu, Y., Giver, C.R., Sharma, A., Li, J.M., Darlak, K.A., Owens, L.M., Roback, J.D., Galipeau, J., and Waller, E.K. (2012). IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood 119, 1075–1085.CrossRefPubMedPubMedCentralGoogle Scholar
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F., and Velardi, A. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097–2100.CrossRefPubMedGoogle Scholar
- Ullrich, E., Salzmann-Manrique, E., Bakhtiar, S., Bremm, M., Gerstner, S., Herrmann, E., Bader, P., Hoffmann, P., Holler, E., Edinger, M., and Wolff, D. (2016). Relation between acute GVHD and NK cell subset reconstitution following allogeneic stem cell transplantation. Front Immunol 7, 595.CrossRefPubMedPubMedCentralGoogle Scholar
- Yan, C.H., Liu, D.H., Liu, K.Y., Xu, L.P., Liu, Y.R., Chen, H., Han, W., Wang, Y., Qin, Y.Z., and Huang, X.J. (2012). Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 119, 3256–3262.CrossRefPubMedGoogle Scholar
- Zhao, X., Gao, F., Zhang, X., Wang, Y., Xu, L., Liu, K., Zhao, X., Chang, Y., Wei, H., Chen, H., Chen, Y., Jiang, Z., and Huang, X. (2016a). Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. Sci China Life Sci 59, 1139–1148.CrossRefPubMedGoogle Scholar
- Zhao, X.Y., Zhao, X.S., Wang, Y.T., Chen, Y.H., Xu, L.P., Zhang, X.H., Han, W., Chen, H., Wang, Y., Yan, C.H., Wang, F.R., Wang, J.Z., Liu, K.Y., Chang, Y.J., and Huang, X.J. (2016b). Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: a randomized study. Oncoimmunology 5, e1250992.CrossRefPubMedPubMedCentralGoogle Scholar